Biontech SE- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Biontech SE 公司

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SE简介



公司代码BNTX

公司名称Biontech SE

上市日期Oct 10, 2019

CEOSahin (Ugur)

员工数量6772

证券类型Depository Receipt

年结日Oct 10

公司地址An der Goldgrube 12

城市MAINZ

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Germany

邮编55131

电话4949613190840

网址https://www.biontech.com/

公司代码BNTX

上市日期Oct 10, 2019

CEOSahin (Ugur)

Biontech SE公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Sierk Poetting, Ph.D.

Chief Operating Officer, Member of the Management Board

767.54K

+12755.00%

Dr. Ulrich Wandschneider, Ph.D.

Independent Deputy Chairman of the Supervisory Board

1.48K

--

Mr. James Ryan

Member of the Management Board, Chief Legal Officer

790.00

+790.00%

Prof. Rudolf Staudigl, Ph.D.

Independent Member of the Supervisory Board

400.00

--

Prof. Anja Morawietz, Ph.D.

Independent Member of the Supervisory Board

240.00

--

Prof. Ugur Sahin, M.D.

Chief Executive Officer, Member of the Management Board

--

Dr. Oezlem Tuereci, M.D.

Chief Medical Office, Member of the Management Board

--

Mr. Helmut Jeggle

Independent Chairman of the Supervisory Board

--

Mr. Michael Motschmann

Independent Member of the Supervisory Board

--

Mr. Michael Horowicz

Director, Investor Relations

--

名称

名称/职务

职务

持股

持股变动

Dr. Sierk Poetting, Ph.D.

Chief Operating Officer, Member of the Management Board

767.54K

+12755.00%

Dr. Ulrich Wandschneider, Ph.D.

Independent Deputy Chairman of the Supervisory Board

1.48K

--

Mr. James Ryan

Member of the Management Board, Chief Legal Officer

790.00

+790.00%

Prof. Rudolf Staudigl, Ph.D.

Independent Member of the Supervisory Board

400.00

--

Prof. Anja Morawietz, Ph.D.

Independent Member of the Supervisory Board

240.00

--

Prof. Ugur Sahin, M.D.

Chief Executive Officer, Member of the Management Board

--

收入明细

单位: USD更新时间: 3月12日周三

FY2019

FY2018

FY2017

业务USD

名称

营收

占比

Collaboration Revenue

84.43M

77.75%

Revenues from Other Sales Transactions

24.16M

22.25%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Collaboration Revenue

84.43M

77.75%

Revenues from Other Sales Transactions

24.16M

22.25%

股东统计

更新时间: 2月2日周一

持股股东

股东类型

持股股东

占比

AT Impf GmbH

39.32%

Medine GmbH

15.49%

Fidelity Management & Research Company LLC

1.92%

T. Rowe Price Investment Management, Inc.

1.87%

Flossbach von Storch AG

1.62%

其他

39.78%

持股股东

占比

AT Impf GmbH

39.32%

Medine GmbH

15.49%

Fidelity Management & Research Company LLC

1.92%

T. Rowe Price Investment Management, Inc.

1.87%

Flossbach von Storch AG

1.62%

其他

39.78%

股东类型

持股股东

占比

Corporation

55.45%

Investment Advisor

11.61%

Investment Advisor/Hedge Fund

3.54%

Individual Investor

1.95%

Research Firm

1.11%

Hedge Fund

0.98%

Sovereign Wealth Fund

0.71%

Pension Fund

0.16%

Bank and Trust

0.14%

其他

24.34%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

771

54.72M

25.43%

-10.33K

2025Q3

808

54.84M

25.69%

-1.45M

2025Q2

821

56.21M

24.34%

+2.26M

2025Q1

832

54.17M

23.64%

-2.66M

2024Q4

855

52.85M

22.63%

+3.24M

2024Q3

827

49.68M

20.44%

+4.23M

2024Q2

801

45.24M

20.73%

+361.30K

2024Q1

817

44.34M

21.44%

-6.62M

2023Q4

879

44.00M

20.40%

+3.38M

2023Q3

904

40.73M

20.46%

-291.47K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

AT Impf GmbH

101.85M

40.33%

-636.54K

-0.62%

Dec 31, 2024

Medine GmbH

40.13M

15.89%

-304.48K

-0.75%

Mar 31, 2025

Fidelity Management & Research Company LLC

4.98M

1.97%

-2.00M

-28.65%

Sep 30, 2025

T. Rowe Price Investment Management, Inc.

4.83M

1.91%

+1.24M

+34.32%

Sep 30, 2025

Flossbach von Storch AG

4.23M

1.68%

-65.00

-0.00%

Sep 30, 2025

PRIMECAP Management Company

3.87M

1.53%

-130.70K

-3.27%

Sep 30, 2025

Dodge & Cox

3.65M

1.44%

+2.77M

+315.65%

Sep 30, 2025

Sahin (Ugur MD)

2.05M

0.81%

-724.50K

-26.11%

Mar 31, 2025

Pfizer Inc

1.66M

0.66%

-2.00M

-54.67%

Sep 30, 2025

Temasek Holdings Pte. Ltd.

1.51M

0.6%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Langar Global HealthTech ETF

4.06%

iShares Genomics Immunology and Healthcare ETF

3.6%

First Trust NYSE Arca Biotechnology Index Fund

3.42%

Global X Genomics & Biotechnology ETF

3.11%

WisdomTree BioRevolution Fund

2.74%

Franklin Genomic Advancements ETF

2.46%

VanEck Biotech ETF

2.38%

Virtus LifeSci Biotech Products ETF

1.58%

ProShares Ultra Nasdaq Biotechnology

1.02%

Invesco Nasdaq Biotechnology ETF

1.01%

Langar Global HealthTech ETF

占比4.06%

iShares Genomics Immunology and Healthcare ETF

占比3.6%

First Trust NYSE Arca Biotechnology Index Fund

占比3.42%

Global X Genomics & Biotechnology ETF

占比3.11%

WisdomTree BioRevolution Fund

占比2.74%

Franklin Genomic Advancements ETF

占比2.46%

VanEck Biotech ETF

占比2.38%

Virtus LifeSci Biotech Products ETF

占比1.58%

ProShares Ultra Nasdaq Biotechnology

占比1.02%

Invesco Nasdaq Biotechnology ETF

占比1.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据